Posted by Michael Wonder on 11 Jan 2022
COUR Pharmaceuticals receives FDA fast track designation for CNP-104 for the treatment of primary biliary cholangitis
10 January 2021 - COUR Pharmaceuticals today announced the U.S. FDA granted fast track designation to the Company's investigational therapy CNP-104 for the treatment of primary biliary cholangitis.
CNP-104 aims to reprogram the immune system to address autoimmune causes of primary biliary cholangitis.
